浸润性乳腺导管癌与原位导管癌分子标志物的临床研究

目的 寻找并探讨乳腺癌组织可能分子标志物的表达及其临床意义。方法 应用免疫组织化学方法分别检测浸润性乳腺导管癌、乳腺导管原位癌与乳腺增生症组织中BRCA1、BRCA2、C-erbB-2、P53、 Bcl-2 的表达情况，分析其改变原因及与浸润性乳腺癌发生的相关关系。结果 100 例浸润性乳腺癌中，分子标志物的表达（BRCA1、BRCA2、C-erbB-2、P53、 Bcl-2）与乳腺导管原位癌及乳腺增生症相比，均发生了一定程度的变化，其中BRCA1 和P53 表达情况的改变与浸润性乳腺癌的发 生相关（P<0.05）。结论 BRCA1 和P53 基因蛋白表达可以作为乳腺癌预后的敏感因子及评估乳腺癌生物学行为和预后的参考指标。

Clinical significance of molecular markers expression in invasive ductal breast cancer and ductal carcinoma in situ

Objective To explore the clinical significance of molecular markers expression in invasive ductal breast cancer and ductal carcinoma in situ. Methods SP immunohistochemical were used to detect the expression of molecular markers（BRCA1, BRCA2, C-erbB-2, P53, Bcl-2） in 100 cases of invasive ductal breast cancer, 60 cases of ductal carcinoma in situ, and 100 cases of Hyperplastic disease. The changes reasons and correlation between molecular markers and breast cancer were analyzed. Results Contrast of ductal carcinoma in situ and Hyperplastic disease, biological molecular markers of 100 cases of invasive ductal breast cancer (BRCA1, BRCA2, C-erbB-2, P53, Bcl-2) all had some changes, and the changes of BRCA1, P53 expression were correlated with breast cancer（P<0.05）. Conclusion Expression of BRCA1, P53 protein can be helpful in the prediction of the biological behavior and prognosis of invasive ductal breast cancer.